- Home
- ZLAB vs FIHL Comparison
ZLAB vs FIHL Comparison
Compare ZLAB & FIHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZLAB | FIHL |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2017 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | FIHL |
|---|---|---|
| Price | $17.60 | $19.62 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $57.22 | $21.14 |
| AVG Volume (30 Days) | ★ 856.8K | 615.0K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 3.07% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $441,629,000.00 | ★ $2,573,400,000.00 |
| Revenue This Year | $26.16 | $9.79 |
| Revenue Next Year | $30.62 | $9.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.14 | 11.89 |
| 52 Week Low | $16.82 | $14.17 |
| 52 Week High | $44.34 | $19.83 |
Technical Indicators
Market Signals| Indicator | ZLAB | FIHL |
|---|---|---|
| Relative Strength Index (RSI) | 34.99 | 61.84 |
| Support Level | $17.50 | $19.34 |
| Resistance Level | $19.01 | $19.83 |
| Average True Range (ATR) | 0.61 | 0.40 |
| MACD | 0.27 | 0.04 |
| Stochastic Oscillator | 35.16 | 86.41 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.